SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Hana Biosciences (Nasdaq:HNAB), a biopharmaceutical company focused on advancing cancer care, today announced the filing of a request for a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for the design of a proposed registration trial for Marqibo® (vincristine sulfate liposomes injection) in adults with acute lymphoblastic leukemia (ALL) in second relapse and beyond.
